[1]
Bernardini, N., Skroza, N., Rossi, G., Mambrin, A., Tolino, E., Marraffa, F., Caviglia, M., Di Guardo, A., Volpe, S., Proietti, I. and Potenza, C. 2022. Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema. Dermatology Reports. 14, 4 (Nov. 2022). DOI:https://doi.org/10.4081/dr.2022.9447.